Immune training enhances anti-viral responses and improves outcomes in Pax5 −/+ mice susceptible to chronic infection

Abstract Viral infections pose a significant global burden. Host susceptibility to pathogens is determined by many factors including genetic variation that can lead to immunodeficient or dysregulated antiviral immune responses. Pax5 heterozygosity (Pax5 −/+), resulting in reduced PAX5 levels in mice...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhe Lu, Olivia Stencel, Wei Liu, Eleni Vasileiou, Haifeng C Xu, Piyush Pandey, Paweł Stachura, Abdelrahman Elwy, Anastassia Tsombal, Ann-Sophie Mai, Franziska Auer, Mina N F Morcos, Maximilian Seidl, Sarah Koziel, Peter-Martin Bruch, Sascha Dietrich, Sarah Elitzur, Gunther Hartmann, Karl S Lang, Stefan Janssen, Ute Fischer, Sanil Bhatia, Philipp A Lang, Arndt Borkhardt, Julia Hauer, Aleksandra A Pandyra
Format: Article
Language:English
Published: Springer Nature 2025-03-01
Series:EMBO Molecular Medicine
Subjects:
Online Access:https://doi.org/10.1038/s44321-025-00208-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849726097801871360
author Zhe Lu
Olivia Stencel
Wei Liu
Eleni Vasileiou
Haifeng C Xu
Piyush Pandey
Paweł Stachura
Abdelrahman Elwy
Anastassia Tsombal
Ann-Sophie Mai
Franziska Auer
Mina N F Morcos
Maximilian Seidl
Sarah Koziel
Peter-Martin Bruch
Sascha Dietrich
Sarah Elitzur
Gunther Hartmann
Karl S Lang
Stefan Janssen
Ute Fischer
Sanil Bhatia
Philipp A Lang
Arndt Borkhardt
Julia Hauer
Aleksandra A Pandyra
author_facet Zhe Lu
Olivia Stencel
Wei Liu
Eleni Vasileiou
Haifeng C Xu
Piyush Pandey
Paweł Stachura
Abdelrahman Elwy
Anastassia Tsombal
Ann-Sophie Mai
Franziska Auer
Mina N F Morcos
Maximilian Seidl
Sarah Koziel
Peter-Martin Bruch
Sascha Dietrich
Sarah Elitzur
Gunther Hartmann
Karl S Lang
Stefan Janssen
Ute Fischer
Sanil Bhatia
Philipp A Lang
Arndt Borkhardt
Julia Hauer
Aleksandra A Pandyra
author_sort Zhe Lu
collection DOAJ
description Abstract Viral infections pose a significant global burden. Host susceptibility to pathogens is determined by many factors including genetic variation that can lead to immunodeficient or dysregulated antiviral immune responses. Pax5 heterozygosity (Pax5 −/+), resulting in reduced PAX5 levels in mice, mimics germline or somatic PAX5 dysregulation contributing to diseases such as childhood B-cell precursor acute lymphoblastic leukemia (B-ALL). In contrast to the well-characterized roles of PAX5 during early B-cell development, little is known about how Pax5 heterozygosity impacts antiviral responses. We infected Pax5 −/+ mice with the noncytopathic Lymphocytic Choriomeningitis Virus (LCMV) and found that infection with the chronic Docile strain resulted in decreased survival of Pax5 −/+ mice. While early adaptive CD8+ T-cell (CTL) immunity was robust in Pax5 −/+ mice, LCMV-specific neutralizing antibody production was compromised leading to impaired long-term viral clearance and a pro-inflammatory milieu in the bone marrow (BM). Here we show that survival outcomes were improved upon prophylactic treatment with the β-glucan immune trainer through induction of heterologous protection against chronic infection. β-Glucan enhanced viral clearance, CTL immunity, neutralizing antibody production and reduced monocyte immunosuppression in multiple LCMV-resident host organs. New insight from this study will help design effective prophylactic treatment strategies against chronic viral infections, particularly in genetically predisposed susceptible hosts.
format Article
id doaj-art-2d44ad874bbf4c8b833e156fddacebeb
institution DOAJ
issn 1757-4684
language English
publishDate 2025-03-01
publisher Springer Nature
record_format Article
series EMBO Molecular Medicine
spelling doaj-art-2d44ad874bbf4c8b833e156fddacebeb2025-08-20T03:10:18ZengSpringer NatureEMBO Molecular Medicine1757-46842025-03-0117469672110.1038/s44321-025-00208-4Immune training enhances anti-viral responses and improves outcomes in Pax5 −/+ mice susceptible to chronic infectionZhe Lu0Olivia Stencel1Wei Liu2Eleni Vasileiou3Haifeng C Xu4Piyush Pandey5Paweł Stachura6Abdelrahman Elwy7Anastassia Tsombal8Ann-Sophie Mai9Franziska Auer10Mina N F Morcos11Maximilian Seidl12Sarah Koziel13Peter-Martin Bruch14Sascha Dietrich15Sarah Elitzur16Gunther Hartmann17Karl S Lang18Stefan Janssen19Ute Fischer20Sanil Bhatia21Philipp A Lang22Arndt Borkhardt23Julia Hauer24Aleksandra A Pandyra25Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityDepartment of Molecular Medicine II, Medical Faculty and University Hospital, Heinrich-Heine-UniversityDepartment of Molecular Medicine II, Medical Faculty and University Hospital, Heinrich-Heine-UniversityDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityInstitute of Immunology, Medical Faculty, University of Duisburg-EssenDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)Technical University of Munich, TUM School of Medicine and Health, Department of PediatricsTechnical University of Munich, TUM School of Medicine and Health, Department of PediatricsInstitute of Pathology, Medical Faculty, Heinrich-Heine-UniversityCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)Faculty of Medicine, Tel-Aviv UniversityInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital BonnInstitute of Immunology, Medical Faculty, University of Duisburg-EssenAlgorithmic Bioinformatics, Department of Biology and Chemistry, Justus Liebig UniversityDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityInstitute of Immunology, Medical Faculty, University of Duisburg-EssenDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityTechnical University of Munich, TUM School of Medicine and Health, Department of PediatricsDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityAbstract Viral infections pose a significant global burden. Host susceptibility to pathogens is determined by many factors including genetic variation that can lead to immunodeficient or dysregulated antiviral immune responses. Pax5 heterozygosity (Pax5 −/+), resulting in reduced PAX5 levels in mice, mimics germline or somatic PAX5 dysregulation contributing to diseases such as childhood B-cell precursor acute lymphoblastic leukemia (B-ALL). In contrast to the well-characterized roles of PAX5 during early B-cell development, little is known about how Pax5 heterozygosity impacts antiviral responses. We infected Pax5 −/+ mice with the noncytopathic Lymphocytic Choriomeningitis Virus (LCMV) and found that infection with the chronic Docile strain resulted in decreased survival of Pax5 −/+ mice. While early adaptive CD8+ T-cell (CTL) immunity was robust in Pax5 −/+ mice, LCMV-specific neutralizing antibody production was compromised leading to impaired long-term viral clearance and a pro-inflammatory milieu in the bone marrow (BM). Here we show that survival outcomes were improved upon prophylactic treatment with the β-glucan immune trainer through induction of heterologous protection against chronic infection. β-Glucan enhanced viral clearance, CTL immunity, neutralizing antibody production and reduced monocyte immunosuppression in multiple LCMV-resident host organs. New insight from this study will help design effective prophylactic treatment strategies against chronic viral infections, particularly in genetically predisposed susceptible hosts.https://doi.org/10.1038/s44321-025-00208-4Trained ImmunityChronic InfectionLCMVPAX5β-glucan
spellingShingle Zhe Lu
Olivia Stencel
Wei Liu
Eleni Vasileiou
Haifeng C Xu
Piyush Pandey
Paweł Stachura
Abdelrahman Elwy
Anastassia Tsombal
Ann-Sophie Mai
Franziska Auer
Mina N F Morcos
Maximilian Seidl
Sarah Koziel
Peter-Martin Bruch
Sascha Dietrich
Sarah Elitzur
Gunther Hartmann
Karl S Lang
Stefan Janssen
Ute Fischer
Sanil Bhatia
Philipp A Lang
Arndt Borkhardt
Julia Hauer
Aleksandra A Pandyra
Immune training enhances anti-viral responses and improves outcomes in Pax5 −/+ mice susceptible to chronic infection
EMBO Molecular Medicine
Trained Immunity
Chronic Infection
LCMV
PAX5
β-glucan
title Immune training enhances anti-viral responses and improves outcomes in Pax5 −/+ mice susceptible to chronic infection
title_full Immune training enhances anti-viral responses and improves outcomes in Pax5 −/+ mice susceptible to chronic infection
title_fullStr Immune training enhances anti-viral responses and improves outcomes in Pax5 −/+ mice susceptible to chronic infection
title_full_unstemmed Immune training enhances anti-viral responses and improves outcomes in Pax5 −/+ mice susceptible to chronic infection
title_short Immune training enhances anti-viral responses and improves outcomes in Pax5 −/+ mice susceptible to chronic infection
title_sort immune training enhances anti viral responses and improves outcomes in pax5 mice susceptible to chronic infection
topic Trained Immunity
Chronic Infection
LCMV
PAX5
β-glucan
url https://doi.org/10.1038/s44321-025-00208-4
work_keys_str_mv AT zhelu immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT oliviastencel immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT weiliu immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT elenivasileiou immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT haifengcxu immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT piyushpandey immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT pawełstachura immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT abdelrahmanelwy immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT anastassiatsombal immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT annsophiemai immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT franziskaauer immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT minanfmorcos immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT maximilianseidl immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT sarahkoziel immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT petermartinbruch immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT saschadietrich immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT sarahelitzur immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT guntherhartmann immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT karlslang immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT stefanjanssen immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT utefischer immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT sanilbhatia immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT philippalang immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT arndtborkhardt immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT juliahauer immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection
AT aleksandraapandyra immunetrainingenhancesantiviralresponsesandimprovesoutcomesinpax5micesusceptibletochronicinfection